Ultrasound contrast developer Acusphere has entered into a lease agreement for 58,000 square feet of commercial manufacturing space in Tewksbury, MA. The Watertown, MA-based vendor said it intends to develop the facility to meet its anticipated initial commercial production needs for its AI-700 ultrasound contrast agent.
AI-700 is in phase III clinical trials, and is designed for the detection of coronary heart disease. Acusphere said it currently manufactures the agent outside of Massachusetts.
By AuntMinnie.com staff writersJuly 23, 2004
Related Reading
Acusphere, Nycomed ink European partnership, July 7, 2004
Ultrasound firm Acusphere launches IPO, October 15, 2003
Acusphere gets financing for development, April 21, 2003
Acusphere launches phase III trials, February 26, 2003
Acusphere raises $15 million, July 24, 2002
Copyright © 2004 AuntMinnie.com